5 results about "Autoimmune disease" patented technology

A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10 / IL-18 ratio and IL-10 / IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo- / non-responder.

The invention discloses an application of IOX1 in prevention and / or treatment of autoimmune diseases, and particularly relates to an application of IOX1 in control of Th17-mediated in-vivo inflammation. The inventor screens an epigenetic compound concentration library of an inhibitor for expression of IFN-gamma and IL-17 in Th1 and Th17 cultures, screens and determines that IOX1 is an effective inhibitor for expression of IL-17 in CD4+T cells, and also finds that the IOX1 inhibits expression of I117a by directly targeting activity of TET2 to a promoter in Th17 cells. The inventor further proves that IOX1 plays an anti-inflammatory role in vivo by regulating migration and functions of Th17 cells through a uveitis model, and Th17-mediated in-vivo inflammation can be effectively controlled.